358 related articles for article (PubMed ID: 14519753)
21. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
22. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
24. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L;
Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227
[TBL] [Abstract][Full Text] [Related]
25. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
26. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
[TBL] [Abstract][Full Text] [Related]
27. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
[TBL] [Abstract][Full Text] [Related]
28. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
29. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.
McCaskill-Stevens W; Wilson J; Bryant J; Mamounas E; Garvey L; James J; Cronin W; Wickerham DL
J Natl Cancer Inst; 2004 Dec; 96(23):1762-9. PubMed ID: 15572758
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
31. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
32. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Han W; Han MR; Kang JJ; Bae JY; Lee JH; Bae YJ; Lee JE; Shin HJ; Hwang KT; Hwang SE; Kim SW; Noh DY
BMC Cancer; 2006 Apr; 6():92. PubMed ID: 16608533
[TBL] [Abstract][Full Text] [Related]
33. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
35. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
Neuhouser ML; Aragaki AK; Prentice RL; Manson JE; Chlebowski R; Carty CL; Ochs-Balcom HM; Thomson CA; Caan BJ; Tinker LF; Urrutia RP; Knudtson J; Anderson GL
JAMA Oncol; 2015 Aug; 1(5):611-21. PubMed ID: 26182172
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
Li CI; Daling JR; Porter PL; Tang MT; Malone KE
Cancer Res; 2009 Sep; 69(17):6865-70. PubMed ID: 19706753
[TBL] [Abstract][Full Text] [Related]
37. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Hughes KS; Schnaper LA; Bellon JR; Cirrincione CT; Berry DA; McCormick B; Muss HB; Smith BL; Hudis CA; Winer EP; Wood WC
J Clin Oncol; 2013 Jul; 31(19):2382-7. PubMed ID: 23690420
[TBL] [Abstract][Full Text] [Related]
38. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Sestak I; Distler W; Forbes JF; Dowsett M; Howell A; Cuzick J
J Clin Oncol; 2010 Jul; 28(21):3411-5. PubMed ID: 20547990
[TBL] [Abstract][Full Text] [Related]
39. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
40. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]